Peptide Binding to HLA-E Molecules in Humans, Nonhuman Primates, and Mice Reveals Unique Binding Peptides but Remarkably Conserved Anchor Residues.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 11 2020
Historique:
received: 13 07 2020
accepted: 07 09 2020
pubmed: 7 10 2020
medline: 15 4 2021
entrez: 6 10 2020
Statut: ppublish

Résumé

Ag presentation via the nonclassical MHC class Ib molecule HLA-E, with nearly complete identity between the two alleles expressed in humans, HLA-E*01:01 and HLA-E*01:03, can lead to the activation of unconventional T cells in humans. Despite this virtual genetic monomorphism, differences in peptide repertoires binding to the two allelic variants have been reported. To further dissect and compare peptide binding to HLA-E*01:01 and HLA-E*01:03, we used an UV-mediated peptide exchange binding assay and an HPLC-based competition binding assay. In addition, we investigated binding of these same peptides to Mamu-E, the nonhuman primate homologue of human HLA-E, and to the HLA-E-like molecule Qa-1

Identifiants

pubmed: 33020145
pii: jimmunol.2000810
doi: 10.4049/jimmunol.2000810
pmc: PMC7653511
mid: NIHMS1628612
doi:

Substances chimiques

Antigens 0
Histocompatibility Antigens Class I 0
Peptides 0
Recombinant Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2861-2872

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI141315
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI127133
Pays : United States

Informations de copyright

Copyright © 2020 by The American Association of Immunologists, Inc.

Références

Stem Cells Int. 2015;2015:346714
pubmed: 26366178
J Immunol. 2003 Aug 1;171(3):1369-75
pubmed: 12874227
J Exp Med. 2000 Sep 4;192(5):613-24
pubmed: 10974028
Eur J Immunol. 2001 Dec;31(12):3687-93
pubmed: 11745389
Eur J Immunol. 2012 Jun;42(6):1405-16
pubmed: 22678897
Mol Immunol. 2013 Jan;53(1-2):126-31
pubmed: 22898188
Microbes Infect. 2010 Nov;12(12-13):910-8
pubmed: 20670688
PLoS One. 2019 Jan 23;14(1):e0210252
pubmed: 30673723
Nat Immunol. 2007 Mar;8(3):268-76
pubmed: 17259989
Hum Immunol. 1997 Jan;52(1):33-40
pubmed: 9021407
Antivir Ther. 2005;10(1):95-107
pubmed: 15751767
Nat Protoc. 2006;1(3):1120-32
pubmed: 17406393
Mol Cell. 1998 Mar;1(4):531-41
pubmed: 9660937
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10896-901
pubmed: 12960383
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Curr Protoc Immunol. 2009 Nov;Chapter 18:Unit 18.16
pubmed: 19918947
Nat Immunol. 2006 Mar;7(3):256-64
pubmed: 16474394
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204
pubmed: 9560253
PLoS One. 2017 Aug 2;12(8):e0182296
pubmed: 28767728
Immunol Lett. 2018 Oct;202:65-72
pubmed: 30172717
Trends Biochem Sci. 2000 Mar;25(3):147-50
pubmed: 10694887
PLoS Pathog. 2019 Feb 21;15(2):e1007567
pubmed: 30789961
Eur J Immunol. 1997 May;27(5):1164-9
pubmed: 9174606
Hum Immunol. 2000 Nov;61(11):1059-65
pubmed: 11137208
J Immunol. 2005 Apr 15;174(8):4812-20
pubmed: 15814707
Eur J Immunol. 2018 Feb;48(2):293-305
pubmed: 29124751
Sci Rep. 2017 Jul 4;7(1):4622
pubmed: 28676677
Eur J Immunol. 2020 Jul 27;:
pubmed: 32716529
Science. 2016 Feb 12;351(6274):714-20
pubmed: 26797147
PLoS Pathog. 2010 Feb 26;6(2):e1000782
pubmed: 20195504
PLoS Pathog. 2015 Mar 24;11(3):e1004671
pubmed: 25803478
Int J Mol Sci. 2019 Nov 04;20(21):
pubmed: 31690066
J Immunol Methods. 1997 Jul 14;205(2):201-9
pubmed: 9294602
Nat Commun. 2018 Aug 7;9(1):3137
pubmed: 30087334
Nat Immunol. 2012 Apr 22;13(6):579-86
pubmed: 22522492
Cancer Immunol Res. 2018 Dec;6(12):1524-1536
pubmed: 30352798
Mol Ther. 2018 May 2;26(5):1206-1214
pubmed: 29567312
Hum Immunol. 2000 Nov;61(11):1150-6
pubmed: 11137220
Front Immunol. 2018 Jan 25;9:60
pubmed: 29422902
Hum Immunol. 1992 Mar;33(3):174-84
pubmed: 1618657
J Biol Chem. 2003 Feb 14;278(7):5082-90
pubmed: 12411439
Vaccine. 2019 May 21;37(23):3022-3030
pubmed: 31040086
Immunogenetics. 2016 Jan;68(1):29-41
pubmed: 26552660
Immunol Cell Biol. 2016 Jul;94(6):573-82
pubmed: 26846725
Science. 2019 Oct 18;366(6463):302-303
pubmed: 31624196
J Immunol. 2018 Jan 1;200(1):49-60
pubmed: 29150562
J Immunol. 2012 Jan 1;188(1):302-10
pubmed: 22131332
J Immunol. 1998 May 15;160(10):4951-60
pubmed: 9590243
J Exp Med. 2002 Dec 2;196(11):1473-81
pubmed: 12461082
Eur J Immunol. 2019 Jul;49(7):1052-1066
pubmed: 31091334
PLoS One. 2017 Nov 27;12(11):e0188288
pubmed: 29176828
J Immunol. 2020 Apr 15;204(8):2169-2176
pubmed: 32161099
Immunol Res. 2004;29(1-3):81-92
pubmed: 15181272
J Immunol. 2010 Oct 15;185(8):4625-32
pubmed: 20844204
PLoS Pathog. 2017 May 5;13(5):e1006384
pubmed: 28475642

Auteurs

Paula Ruibal (P)

Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands; and.

Kees L M C Franken (KLMC)

Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands; and.

Krista E van Meijgaarden (KE)

Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands; and.

Joeri J F van Loon (JJF)

Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands; and.

Dirk van der Steen (D)

Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.

Mirjam H M Heemskerk (MHM)

Department of Hematology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.

Tom H M Ottenhoff (THM)

Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands; and t.h.m.ottenhoff@lumc.nl p.ruibal@lumc.nl.

Simone A Joosten (SA)

Department of Infectious Diseases, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH